S. Golding

发表

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

R. Govindan, A. Dingemans, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

98PRetrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib

P. Delmar, M. Coudert, W. Bordogna, 2017 .

Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies

K. Bogman, P. N. Morcos, Carolina Sturm-Pellanda, 2017, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).

R. Govindan, J. Ahn, S. Ou, 2015 .

Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC).

A. Ravaud, B. Melichar, J. Bellmunt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

M. Socinski, R. Govindan, A. Shaw, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017, The New England journal of medicine.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Ruey-min Lee, S. Ou, Gregory Riely, 2014, The Lancet. Oncology.

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

A. Ravaud, B. Melichar, J. Bellmunt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.

P. Delmar, M. Coudert, W. Bordogna, 2018, Journal of comparative effectiveness research.

Population pharmacokinetics (popPK) and exposure-response (ER) analyses bridge J-ALEX to the global population with an alectinib (ALC) 600mg bid dosing regimen.

P. N. Morcos, N. Frey, Tomohiro Tanaka, 2017 .

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

A. Dingemans, S. Ou, F. Barlesi, 2016 .

MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

M. Socinski, A. Shaw, S. Ou, 2017 .

Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017 .

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies ( NP 28673 1 and NP 28761 ) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer

Jie Yang, R. Govindan, A. Shaw, 2017 .